24 10, 2019

meet TAmiRNA 2019

2019-12-09T09:21:53+01:00October 24th, 2019|biomarker, biomarkers, microRNAs, Personalized medicine|0 Comments

2019 TAmiRNA showcases at several conferences 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research, 27 February-2 March 2019, Berlin, Germany 9th international Gene Quantification Event, 18-22 March, Freising-Weihenstephan, Germany ECTS (European Calcified Tissue Society) 2019, 11-14 May 2019, Budapest, Hungary The 9th International Conference on Children’s Bone Health, 22-25 June 2019, Salzburg, Austria British Orthopaedic Society, 4-6 September 2019, Cardiff, UK ASBMR 2019 Annual Meeting, 20-23 September 2019, Orlando, Florida Safety Pharmacology Society Annual Meeting, 23-26 September 2019, Barcelona, Spain Knochen, Muskeln und Gelenke - Update 2019 "Neues aus der Forschung und Klinik", 8-9 November 2019, Berlin, Germany BIO-Europe, 11-13 November 2019, Hamburg, Germany RNA Targeting conference, 26-27 November 2019, Frankfurt. Germany

18 09, 2019

TAmiRNA GmbH is part of the EU-funded Innovative Training Network FIDELIO

2019-12-09T09:21:39+01:00September 18th, 2019|biomarkers, bone diseases, diabetes, microRNAs, Personalized medicine|0 Comments

Diabetes mellitus is a widespread metabolic disease, with negative/adverse effects on many organ systems. Diabetes also significantly affects bone health. An increased risk of bone fractures and impaired fracture healing has been observed in patients, but the mechanisms are not fully understood. In order to investigate the links between diabetes and the bone system, the EU project "FIDELIO" will run for four years starting October 2019. This European Training Network, coordinated by scientists from the Faculty of Medicine of the Technical University of Dresden, is funded by the EU Marie Skłodowska-Curie Actions program with a total of 3.8 million €. FIDELIO aims to train the next generation of scientists in order to tackle the challenges of diabetic [...]

30 04, 2019

TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

2019-12-09T09:20:21+01:00April 30th, 2019|biomarkers, drug development, drug discovery, exosomes, liquid biopsies, microRNAs, Personalized medicine, safety|0 Comments

Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The project is coordinated by the University of Zurich with Pfizer as industry lead, and involves 27 partners (pharmaceutical companies, small and medium-sized enterprises, and academic institutions) from ten European countries and the United States of America. With a total budget of € 28 million, the EU and the pharmaceutical companies involved are financing the [...]

30 04, 2019

TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

2019-12-09T09:21:00+01:00April 30th, 2019|biomarkers, drug development, drug discovery, microRNAs, Personalized medicine, safety, thrombomiR|0 Comments

TAmiRNA and advanceCOR, a drug developing biotechnology company which focuses on personalized medicine in cardiovascular diseases, receive Eurostars project entitled: ”A novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”.  The aim of the Eurostars project is to validate the use of the thrombomiR™ kit for management of anti-thrombotic therapies. The thrombomiR™ kit is a minimally invasive blood test that can determine changes in platelets reactivity (for example due to a therapy), based on the quantitative analysis of microRNAs, Specifically, the thrombomiR™ kit allows the targeted detection and quantitation of platelet-specific microRNAs in blood plasma. The concentration of these microRNAs increases in the course of activation of platelets and decreases as a result of therapeutic inactivation. Thus, [...]

30 03, 2019

Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures.

2019-03-30T09:08:05+01:00March 30th, 2019|biomarker, Liver disease, microRNAs, Personalized medicine|1 Comment

We want to draw your attention to the latest publication of the Department of Surgery, Medical University of Vienna, in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Personalized medicine in liver surgery. Together with colleagues from Medical University Vienna we could show that plasma levels of three miRNAs can accurately predict liver dysfunction prior to surgery. This will allow us to stratify patients into risk groups that need preoperative liver volume augmentation or might even be better off with alternative treatment options. Click here to read the study